Retina

This post-hoc analysis was performed to evaluate immunogenicity over the long term.

Surrozen Inc. announced this week that it has entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for the treatment of retinal diseases.

The setting for this year's Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide the opportunity for clinical interaction between faculty and attendees along with the practicality of information.

Children who develop the pediatric eye cancer retinoblastoma often lose their vision or an eye due to a lack of specific, targeted therapies and a poor molecular understanding of the cancer. Researchers at UT Southwestern and the University of Miami have discovered that a molecule – estrogen-related receptor gamma, or ESRRG – becomes hyperactive and promotes tumor cell survival in retinoblastoma.

New research paves the way for accurate non-invasive screening test that doe not have to be done in the clinic.

A combination of posters, podium presentations, and instructional courses provided invaluable revelations to the ophthalmic community.

A combination of posters, podium presentations and instructional courses provided invaluable revelations to the ophthalmic community.

The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.

Companies are exploring light-sensitive proteins method in patients with advanced disease.

The data analysis showed that the macular thickness decreased across all time periods and in all macular regions for all terciles.

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, William Kearney and Dan Gong, MD, discussed how patients with a unilateral retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

Patients with a unilateral rhegmatogenous retinal detachment frequently ask about the risk of developing an RRD in their fellow eye.

DME showed small significant improvement in study cohort.

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability and safety of faricimab in patients with neovascular AMD.

The AVONELLE-X long-term extension study will continue to evaluate the efficacy, durability, and safety of faricimab in patients with neovascular AMD.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

In a presentation at the American Academy of Ophthalmology’s 2022 annual meeting in Chicago, Ines Lains, MD, PhD, detailed how adjunct treatment with intravitreal antivirals or early pars plana vitrectomy did not improve the rates of retinal detachment in patients diagnosed with acute retinal necrosis.

The results also showed that, compared to use of systemic antivirals alone, treatment with adjunctive intravitreal injections or early pars plana vitrectomy did not affect the time to development of retinal detachments.

The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.

In an announcement at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago, the company noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

At AAO 2022, Dr Justis Ehlers presented a talk entitled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

Data were presented during an oral presentation at the American Academy of Ophthalmology’s 2022 annual meeting at McCormick Place in Chicago.

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."